H101 Combined With Camrelizumab for Recurrent Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
There is no standard treatment for recurrent cervical cancer that progresses or persists
after first-line treatment. The objective response rate of anti-PD-1 antibody treatment is
about 15%. The purpose of this study was to evaluate whether the regimen could improve the
objective response rate by intratumoral injection of oncolytic virus(recombinant human
adenovirus type 5 injection, H101) combined with anti-PD-1 antibody(camrelizumab).